Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab/Envafolimab and NAs for Chronic Hepatitis B
NCT07852091Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab and envafolimab in Chronic Hepatitis B (CHB) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Serum Hepatitis B surface antigen, Serum Hepatitis B Virus DNA and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
sintilimabenvafolimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07852091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852091.